A recent example of such advances is the development of a new class of therapeutic agents based on the discovery of the gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) as a regulator of LDL cholesterol and the discovery that loss-of-function variants in this gene protect against ischaemic heart disease [36]. Here, PCSK9 is linked to heart disorder.